{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:50:28Z","timestamp":1790034628594,"version":"4.0.1"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Obes Rep"],"DOI":"10.1007\/s13679-024-00597-6","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T23:40:21Z","timestamp":1736552421000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Nutritional Strategies for Battling Obesity-Linked Liver Disease: the Role of Medical Nutritional Therapy in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3641-1501","authenticated-orcid":false,"given":"Daniel","family":"Simancas-Racines","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-662X","authenticated-orcid":false,"given":"Giuseppe","family":"Annunziata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4583-8283","authenticated-orcid":false,"given":"Ludovica","family":"Verde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0998-3332","authenticated-orcid":false,"given":"Federica","family":"Fasc\u00ec-Spurio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4234-5524","authenticated-orcid":false,"given":"Claudia","family":"Reytor-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8809-4931","authenticated-orcid":false,"given":"Giovanna","family":"Muscogiuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2228-0141","authenticated-orcid":false,"given":"Evelyn","family":"Frias-Toral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9054-456X","authenticated-orcid":false,"given":"Luigi","family":"Barrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"key":"597_CR1","unstructured":"World Health Organization. Obesity and overweight. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"597_CR2","doi-asserted-by":"publisher","unstructured":"Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143(21). https:\/\/doi.org\/10.1161\/CIR.0000000000000973","DOI":"10.1161\/CIR.0000000000000973"},{"key":"597_CR3","doi-asserted-by":"publisher","unstructured":"Ruze R, Liu T, Zou X, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol (Lausanne). 2023;14. https:\/\/doi.org\/10.3389\/fendo.2023.1161521","DOI":"10.3389\/fendo.2023.1161521"},{"issue":"4","key":"597_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1161\/CIRCULATIONAHA.117.032047","volume":"138","author":"Y Li","year":"2018","unstructured":"Li Y, Pan A, Wang DD, et al. Impact of Healthy Lifestyle Factors on Life Expectancies in the US Population. Circulation. 2018;138(4):345\u201355. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.032047.","journal-title":"Circulation"},{"issue":"1","key":"597_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","volume":"8","author":"J Quek","year":"2023","unstructured":"Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20\u201330. https:\/\/doi.org\/10.1016\/S2468-1253(22)00317-X.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"597_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101133","volume":"29","author":"ME Rinella","year":"2024","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2024;29(1): 101133. https:\/\/doi.org\/10.1016\/j.aohep.2023.101133.","journal-title":"Ann Hepatol"},{"key":"597_CR7","doi-asserted-by":"publisher","unstructured":"Farrell GC, Chitturi S, Lau GKK, Sollano JD, Asia-Pacific Working Party on NAFLD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol. 2007;22(6):775\u2013777. https:\/\/doi.org\/10.1111\/j.1440-1746.2007.05002.x","DOI":"10.1111\/j.1440-1746.2007.05002.x"},{"issue":"7","key":"597_CR8","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J, et al. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999\u20132014.e1. https:\/\/doi.org\/10.1053\/j.gastro.2019.11.312.","journal-title":"Gastroenterology"},{"issue":"1","key":"597_CR9","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039.","journal-title":"J Hepatol"},{"key":"597_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.155937","volume":"157","author":"M Huttasch","year":"2024","unstructured":"Huttasch M, Roden M, Kahl S. Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? Metabolism. 2024;157: 155937. https:\/\/doi.org\/10.1016\/j.metabol.2024.155937.","journal-title":"Metabolism"},{"issue":"4","key":"597_CR11","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","volume":"13","author":"S Singh","year":"2015","unstructured":"Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies. Clin Gastroenterol Hepatol. 2015;13(4):643\u2013654.e9. https:\/\/doi.org\/10.1016\/j.cgh.2014.04.014.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"597_CR12","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1053\/j.gastro.2019.12.054","volume":"158","author":"V Azzu","year":"2020","unstructured":"Azzu V, Vacca M, Virtue S, Allison M, Vidal-Puig A. Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease. Gastroenterology. 2020;158(7):1899\u2013912. https:\/\/doi.org\/10.1053\/j.gastro.2019.12.054.","journal-title":"Gastroenterology"},{"issue":"4","key":"597_CR13","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.aohep.2020.03.001","volume":"19","author":"A Lonardo","year":"2020","unstructured":"Lonardo A, Mantovani A, Lugari S, Targher G. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. Ann Hepatol. 2020;19(4):359\u201366. https:\/\/doi.org\/10.1016\/j.aohep.2020.03.001.","journal-title":"Ann Hepatol"},{"key":"597_CR14","doi-asserted-by":"publisher","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015;149(2):367\u201378.e5; quiz e14\u20135. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.005","DOI":"10.1053\/j.gastro.2015.04.005"},{"issue":"1","key":"597_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/hep.23276","volume":"51","author":"K Promrat","year":"2010","unstructured":"Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51(1):121\u20139. https:\/\/doi.org\/10.1002\/hep.23276.","journal-title":"Hepatology"},{"issue":"5","key":"597_CR16","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1053\/j.gastro.2009.01.048","volume":"136","author":"E Kirk","year":"2009","unstructured":"Kirk E, Reeds DN, Finck BN, Mayurranjan SM, Patterson BW, Klein S. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology. 2009;136(5):1552\u201360. https:\/\/doi.org\/10.1053\/j.gastro.2009.01.048.","journal-title":"Gastroenterology"},{"issue":"8","key":"597_CR17","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1056\/NEJMoa2003697","volume":"383","author":"M Yoshino","year":"2020","unstructured":"Yoshino M, Kayser BD, Yoshino J, et al. Effects of Diet versus Gastric Bypass on Metabolic Function in Diabetes. N Engl J Med. 2020;383(8):721\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2003697.","journal-title":"N Engl J Med"},{"issue":"4","key":"597_CR18","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.cmet.2016.02.005","volume":"23","author":"F Magkos","year":"2016","unstructured":"Magkos F, Fraterrigo G, Yoshino J, et al. Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity. Cell Metab. 2016;23(4):591\u2013601. https:\/\/doi.org\/10.1016\/j.cmet.2016.02.005.","journal-title":"Cell Metab"},{"key":"597_CR19","doi-asserted-by":"publisher","unstructured":"Ali H, Shahzil M, Moond V, et al. Non-Pharmacological Approach to Diet and Exercise in Metabolic-Associated Fatty Liver Disease: Bridging the Gap between Research and Clinical Practice. J Pers Med. 2024;14(1). https:\/\/doi.org\/10.3390\/jpm14010061","DOI":"10.3390\/jpm14010061"},{"issue":"1","key":"597_CR20","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1186\/s12967-024-05408-z","volume":"22","author":"YJ Kwon","year":"2024","unstructured":"Kwon YJ, Choi JE, Hong KW, Lee JW. Interplay of Mediterranean-diet adherence, genetic factors, and metabolic dysfunction-associated steatotic liver disease risk in Korea. J Transl Med. 2024;22(1):591. https:\/\/doi.org\/10.1186\/s12967-024-05408-z.","journal-title":"J Transl Med"},{"issue":"4","key":"597_CR21","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s13679-022-00481-1","volume":"11","author":"G Muscogiuri","year":"2022","unstructured":"Muscogiuri G, Verde L, Sulu C, et al. Mediterranean Diet and Obesity-related Disorders: What is the Evidence? Curr Obes Rep. 2022;11(4):287\u2013304. https:\/\/doi.org\/10.1007\/s13679-022-00481-1.","journal-title":"Curr Obes Rep"},{"key":"597_CR22","doi-asserted-by":"publisher","unstructured":"Dobbie LJ, Burgess J, Hamid A, et al. Effect of a Low-Calorie Dietary Intervention on Liver Health and Body Weight in Adults with Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Overweight\/Obesity: A Systematic Review and Meta-Analysis. Nutrients. 2024;16(7). https:\/\/doi.org\/10.3390\/nu16071030","DOI":"10.3390\/nu16071030"},{"key":"597_CR23","doi-asserted-by":"publisher","unstructured":"De Nucci S, Bonfiglio C, Donvito R, et al. Effects of an Eight Week Very Low-Calorie Ketogenic Diet (VLCKD) on White Blood Cell and Platelet Counts in Relation to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Subjects with Overweight and Obesity. Nutrients. 2023;15(20). https:\/\/doi.org\/10.3390\/nu15204468","DOI":"10.3390\/nu15204468"},{"key":"597_CR24","first-page":"283","volume":"8","author":"F Schaffner","year":"1986","unstructured":"Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis. 1986;8:283\u201398.","journal-title":"Prog Liver Dis"},{"issue":"10","key":"597_CR25","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537\u201364. https:\/\/doi.org\/10.1016\/j.cell.2021.04.015.","journal-title":"Cell"},{"issue":"4","key":"597_CR26","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/hep.28985","volume":"65","author":"F Bril","year":"2017","unstructured":"Bril F, Barb D, Portillo-Sanchez P, et al. Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease. Hepatology. 2017;65(4):1132\u201344. https:\/\/doi.org\/10.1002\/hep.28985.","journal-title":"Hepatology"},{"issue":"2","key":"597_CR27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cmet.2007.12.009","volume":"7","author":"MS Brown","year":"2008","unstructured":"Brown MS, Goldstein JL. Selective versus Total Insulin Resistance: A Pathogenic Paradox. Cell Metab. 2008;7(2):95\u20136. https:\/\/doi.org\/10.1016\/j.cmet.2007.12.009.","journal-title":"Cell Metab"},{"key":"597_CR28","doi-asserted-by":"publisher","unstructured":"Mthembu SXH, Dludla P V, Ziqubu K, et al. The Potential Role of Polyphenols in Modulating Mitochondrial Bioenergetics within the Skeletal Muscle: A Systematic Review of Preclinical Models. Molecules. 2021;26(9). https:\/\/doi.org\/10.3390\/molecules26092791","DOI":"10.3390\/molecules26092791"},{"issue":"12","key":"597_CR29","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1016\/j.cmet.2021.09.010","volume":"33","author":"MA Herman","year":"2021","unstructured":"Herman MA, Birnbaum MJ. Molecular aspects of fructose metabolism and metabolic disease. Cell Metab. 2021;33(12):2329\u201354. https:\/\/doi.org\/10.1016\/j.cmet.2021.09.010.","journal-title":"Cell Metab"},{"issue":"7","key":"597_CR30","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.3390\/cells10071805","volume":"10","author":"JM Eng","year":"2021","unstructured":"Eng JM, Estall JL. Diet-Induced Models of Non-Alcoholic Fatty Liver Disease: Food for Thought on Sugar, Fat, and Cholesterol. Cells. 2021;10(7):1805. https:\/\/doi.org\/10.3390\/cells10071805.","journal-title":"Cells"},{"key":"597_CR31","doi-asserted-by":"publisher","unstructured":"Muriel P, L\u00f3pez-S\u00e1nchez P, Ramos-Tovar E. Fructose and the Liver. Int J Mol Sci. 2021;22(13). https:\/\/doi.org\/10.3390\/ijms22136969","DOI":"10.3390\/ijms22136969"},{"issue":"5","key":"597_CR32","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1080\/10408363.2019.1711360","volume":"57","author":"S Softic","year":"2020","unstructured":"Softic S, Stanhope KL, Boucher J, et al. Fructose and hepatic insulin resistance. Crit Rev Clin Lab Sci. 2020;57(5):308\u201322. https:\/\/doi.org\/10.1080\/10408363.2019.1711360.","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"8","key":"597_CR33","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1007\/s00394-023-03232-7","volume":"62","author":"R Staltner","year":"2023","unstructured":"Staltner R, Burger K, Baumann A, Bergheim I. Fructose: a modulator of intestinal barrier function and hepatic health? Eur J Nutr. 2023;62(8):3113\u201324. https:\/\/doi.org\/10.1007\/s00394-023-03232-7.","journal-title":"Eur J Nutr"},{"key":"597_CR34","doi-asserted-by":"publisher","unstructured":"Grosso G, Laudisio D, Frias-Toral E, et al. Anti-Inflammatory Nutrients and Obesity-Associated Metabolic-Inflammation: State of the Art and Future Direction. Nutrients. 2022;14(6). https:\/\/doi.org\/10.3390\/nu14061137","DOI":"10.3390\/nu14061137"},{"issue":"3","key":"597_CR35","doi-asserted-by":"publisher","first-page":"C375","DOI":"10.1152\/ajpcell.00379.2020","volume":"320","author":"T Kawai","year":"2021","unstructured":"Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 2021;320(3):C375\u201391. https:\/\/doi.org\/10.1152\/ajpcell.00379.2020.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"12","key":"597_CR36","doi-asserted-by":"publisher","first-page":"5755","DOI":"10.1210\/jcem.86.12.8075","volume":"86","author":"BH Goodpaster","year":"2001","unstructured":"Goodpaster BH, He J, Watkins S, Kelley DE. Skeletal Muscle Lipid Content and Insulin Resistance: Evidence for a Paradox in Endurance-Trained Athletes. J Clin Endocrinol Metab. 2001;86(12):5755\u201361. https:\/\/doi.org\/10.1210\/jcem.86.12.8075.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"597_CR37","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","volume":"18","author":"T Kisseleva","year":"2021","unstructured":"Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2021;18(3):151\u201366. https:\/\/doi.org\/10.1038\/s41575-020-00372-7.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"597_CR38","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","volume":"5","author":"Q Ye","year":"2020","unstructured":"Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8):739\u201352. https:\/\/doi.org\/10.1016\/S2468-1253(20)30077-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"597_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384. https:\/\/doi.org\/10.1002\/hep.28431.","journal-title":"Hepatology"},{"issue":"1","key":"597_CR40","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1152\/physrev.00033.2011","volume":"93","author":"A Tchernof","year":"2013","unstructured":"Tchernof A, Despr\u00e9s JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93(1):359\u2013404. https:\/\/doi.org\/10.1152\/physrev.00033.2011.","journal-title":"Physiol Rev"},{"key":"597_CR41","doi-asserted-by":"publisher","unstructured":"Non-alcoholic Fatty Liver Disease Study Group, Lonardo A, Bellentani S, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis. 2015;47(12):997\u20131006. https:\/\/doi.org\/10.1016\/j.dld.2015.08.004","DOI":"10.1016\/j.dld.2015.08.004"},{"issue":"2","key":"597_CR42","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149(2):389\u201397.e10. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.043.","journal-title":"Gastroenterology"},{"issue":"1","key":"597_CR43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cld.2017.08.003","volume":"22","author":"CC Lindenmeyer","year":"2018","unstructured":"Lindenmeyer CC, McCullough AJ. The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View. Clin Liver Dis. 2018;22(1):11\u201321. https:\/\/doi.org\/10.1016\/j.cld.2017.08.003.","journal-title":"Clin Liver Dis"},{"issue":"4 Pt 1","key":"597_CR44","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1053\/jhep.2000.17894","volume":"32","author":"A Poonawala","year":"2000","unstructured":"Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology. 2000;32(4 Pt 1):689\u201392. https:\/\/doi.org\/10.1053\/jhep.2000.17894.","journal-title":"Hepatology"},{"issue":"2","key":"597_CR45","doi-asserted-by":"publisher","first-page":"168","DOI":"10.5009\/gnl19069","volume":"14","author":"AA Li","year":"2020","unstructured":"Li AA, Ahmed A, Kim D. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Gut Liver. 2020;14(2):168\u201378. https:\/\/doi.org\/10.5009\/gnl19069.","journal-title":"Gut Liver"},{"issue":"3","key":"597_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2024.101491","volume":"29","author":"M Nemer","year":"2024","unstructured":"Nemer M, Osman F, Said A. Dietary macro and micronutrients associated with MASLD: Analysis of a national US cohort database. Ann Hepatol. 2024;29(3): 101491. https:\/\/doi.org\/10.1016\/j.aohep.2024.101491.","journal-title":"Ann Hepatol"},{"key":"597_CR47","doi-asserted-by":"publisher","first-page":"1251861","DOI":"10.3389\/fnut.2023.1251861","volume":"10","author":"P Ramaiah","year":"2023","unstructured":"Ramaiah P, Jamel Baljon K, Alsulami SA, Lindsay GM, Chinnasamy L. Diet quality indices and odds of metabolic dysfunction-associated fatty liver disease: a case-control study. Front Nutr. 2023;10:1251861. https:\/\/doi.org\/10.3389\/fnut.2023.1251861.","journal-title":"Front Nutr"},{"issue":"3","key":"597_CR48","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/s41430-022-01240-0","volume":"77","author":"A Doustmohammadian","year":"2023","unstructured":"Doustmohammadian A, Amirkalali B, Gholizadeh E, et al. Mediators of dietary diversity score (DDS) on NAFLD in Iranian adults: a structural equation modeling study. Eur J Clin Nutr. 2023;77(3):370\u20139. https:\/\/doi.org\/10.1038\/s41430-022-01240-0.","journal-title":"Eur J Clin Nutr"},{"issue":"10","key":"597_CR49","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S0002-8223(95)00300-2","volume":"95","author":"ET Kennedy","year":"1995","unstructured":"Kennedy ET, Ohls J, Carlson S, Fleming K. The Healthy Eating Index. J Am Diet Assoc. 1995;95(10):1103\u20138. https:\/\/doi.org\/10.1016\/S0002-8223(95)00300-2.","journal-title":"J Am Diet Assoc"},{"issue":"Suppl 1","key":"597_CR50","first-page":"70","volume":"17","author":"E Kennedy","year":"2008","unstructured":"Kennedy E. Putting the pyramid into action: the Healthy Eating Index and Food Quality Score. Asia Pac J Clin Nutr. 2008;17(Suppl 1):70\u20134.","journal-title":"Asia Pac J Clin Nutr"},{"issue":"5","key":"597_CR51","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"K Cusi","year":"2022","unstructured":"Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28(5):528\u201362. https:\/\/doi.org\/10.1016\/j.eprac.2022.03.010.","journal-title":"Endocr Pract"},{"issue":"S1","key":"597_CR52","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/liv.14360","volume":"40","author":"G Bern\u00e1","year":"2020","unstructured":"Bern\u00e1 G, Romero-Gomez M. The role of nutrition in non-alcoholic fatty liver disease: Pathophysiology and management. Liver Int. 2020;40(S1):102\u20138. https:\/\/doi.org\/10.1111\/liv.14360.","journal-title":"Liver Int"},{"issue":"8","key":"597_CR53","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1001\/jamainternmed.2018.2933","volume":"178","author":"DS Ludwig","year":"2018","unstructured":"Ludwig DS, Ebbeling CB. The Carbohydrate-Insulin Model of Obesity: Beyond \u201cCalories In, Calories Out.\u201d JAMA Intern Med. 2018;178(8):1098\u2013103. https:\/\/doi.org\/10.1001\/jamainternmed.2018.2933.","journal-title":"JAMA Intern Med"},{"issue":"2","key":"597_CR54","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ajcnut.2024.06.006","volume":"120","author":"A London","year":"2024","unstructured":"London A, Richter MM, Sj\u00f8berg KA, et al. The impact of short-term eucaloric low- and high-carbohydrate diets on liver triacylglycerol content in males with overweight and obesity: a randomized crossover study. Am J Clin Nutr. 2024;120(2):283\u201393. https:\/\/doi.org\/10.1016\/j.ajcnut.2024.06.006.","journal-title":"Am J Clin Nutr"},{"key":"597_CR55","doi-asserted-by":"publisher","unstructured":"Barrea L, Caprio M, Grassi D, et al. A New Nomenclature for the Very Low-Calorie Ketogenic Diet (VLCKD): Very Low-Energy Ketogenic Therapy (VLEKT). Ketodiets and Nutraceuticals Expert Panels: \u201cKetoNut\u201d, Italian Society of Nutraceuticals (SINut) and the Italian Association of Dietetics and Clinical Nutrition (ADI). Curr Nutr Rep. 2024;13(3):552\u2013556. https:\/\/doi.org\/10.1007\/s13668-024-00560-w","DOI":"10.1007\/s13668-024-00560-w"},{"issue":"2","key":"597_CR56","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1159\/000515381","volume":"14","author":"G Muscogiuri","year":"2021","unstructured":"Muscogiuri G, El Ghoch M, Colao A, Hassapidou M, Yumuk V, Busetto L. European Guidelines for Obesity Management in Adults with a Very Low-Calorie Ketogenic Diet: A Systematic Review and Meta-Analysis. Obes Facts. 2021;14(2):222\u201345. https:\/\/doi.org\/10.1159\/000515381.","journal-title":"Obes Facts"},{"issue":"11","key":"597_CR57","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s40618-019-01061-2","volume":"42","author":"M Caprio","year":"2019","unstructured":"Caprio M, Infante M, Moriconi E, et al. Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE). J Endocrinol Invest. 2019;42(11):1365\u201386. https:\/\/doi.org\/10.1007\/s40618-019-01061-2.","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"597_CR58","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/s12967-019-2104-z","volume":"17","author":"G Muscogiuri","year":"2019","unstructured":"Muscogiuri G, Barrea L, Laudisio D, et al. The management of very low-calorie ketogenic diet in obesity outpatient clinic: a practical guide. J Transl Med. 2019;17(1):356. https:\/\/doi.org\/10.1186\/s12967-019-2104-z.","journal-title":"J Transl Med"},{"issue":"3","key":"597_CR59","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40618-023-02258-2","volume":"47","author":"L Barrea","year":"2024","unstructured":"Barrea L, Caprio M, Camajani E, et al. Ketogenic nutritional therapy (KeNuT)\u2014a multi-step dietary model with meal replacements for the management of obesity and its related metabolic disorders: a consensus statement from the working group of the Club of the Italian Society of Endocrinology (SIE)\u2014diet therapies in endocrinology and metabolism. J Endocrinol Invest. 2024;47(3):487\u2013500. https:\/\/doi.org\/10.1007\/s40618-023-02258-2.","journal-title":"J Endocrinol Invest"},{"issue":"10","key":"597_CR60","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.3390\/nu16101408","volume":"16","author":"R Rinaldi","year":"2024","unstructured":"Rinaldi R, De Nucci S, Donghia R, et al. Gender Differences in Liver Steatosis and Fibrosis in Overweight and Obese Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease before and after 8 Weeks of Very Low-Calorie Ketogenic Diet. Nutrients. 2024;16(10):1408. https:\/\/doi.org\/10.3390\/nu16101408.","journal-title":"Nutrients"},{"key":"597_CR61","doi-asserted-by":"publisher","unstructured":"Sila A, De Nucci S, Bonfiglio C, et al. Higher-Level Steatosis Is Associated with a Greater Decrease in Metabolic Dysfunction-Associated Steatoic Liver Disease after Eight Weeks of a Very Low-Calorie Ketogenic Diet (VLCKD) in Subjects Affected by Overweight and Obesity. Nutrients. 2024;16(6). https:\/\/doi.org\/10.3390\/nu16060874","DOI":"10.3390\/nu16060874"},{"key":"597_CR62","doi-asserted-by":"publisher","first-page":"6621644","DOI":"10.1155\/2021\/6621644","volume":"2021","author":"HY Li","year":"2021","unstructured":"Li HY, Gan RY, Shang A, et al. Plant-Based Foods and Their Bioactive Compounds on Fatty Liver Disease: Effects, Mechanisms, and Clinical Application. Oxid Med Cell Longev. 2021;2021:6621644. https:\/\/doi.org\/10.1155\/2021\/6621644.","journal-title":"Oxid Med Cell Longev"},{"key":"597_CR63","doi-asserted-by":"publisher","unstructured":"Tian A, Sun Z, Zhang M, Li J, Pan X, Chen P. Associations between dietary fatty acid patterns and non-alcoholic fatty liver disease in typical dietary population: A UK biobank study. Front Nutr. 2023;10. https:\/\/doi.org\/10.3389\/fnut.2023.1117626","DOI":"10.3389\/fnut.2023.1117626"},{"issue":"6","key":"597_CR64","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/hep4.1906","volume":"6","author":"V \u0160m\u00edd","year":"2022","unstructured":"\u0160m\u00edd V, Dvo\u0159\u00e1k K, \u0160ediv\u00fd P, et al. Effect of Omega-3 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients With Metabolic Syndrome and NAFLD. Hepatol Commun. 2022;6(6):1336\u201349. https:\/\/doi.org\/10.1002\/hep4.1906.","journal-title":"Hepatol Commun"},{"issue":"3","key":"597_CR65","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3945\/jn.112.171322","volume":"143","author":"CM Depner","year":"2013","unstructured":"Depner CM, Philbrick KA, Jump DB. Docosahexaenoic Acid Attenuates Hepatic Inflammation, Oxidative Stress, and Fibrosis without Decreasing Hepatosteatosis in a Ldlr Mouse Model of Western Diet-Induced Nonalcoholic Steatohepatitis. J Nutr. 2013;143(3):315\u201323. https:\/\/doi.org\/10.3945\/jn.112.171322.","journal-title":"J Nutr"},{"issue":"2","key":"597_CR66","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.plefa.2012.12.001","volume":"88","author":"A Lamaziere","year":"2013","unstructured":"Lamaziere A, Wolf C, Barbe U, Bausero P, Visioli F. Lipidomics of hepatic lipogenesis inhibition by omega 3 fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2013;88(2):149\u201354. https:\/\/doi.org\/10.1016\/j.plefa.2012.12.001.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"11","key":"597_CR67","doi-asserted-by":"publisher","first-page":"5018","DOI":"10.3390\/nu6115018","volume":"6","author":"CJ Green","year":"2014","unstructured":"Green CJ, Hodson L. The influence of dietary fat on liver fat accumulation. Nutrients. 2014;6(11):5018\u201333. https:\/\/doi.org\/10.3390\/nu6115018.","journal-title":"Nutrients"},{"issue":"1","key":"597_CR68","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1741-7015-12-112","volume":"12","author":"A Trichopoulou","year":"2014","unstructured":"Trichopoulou A, Mart\u00ednez-Gonz\u00e1lez MA, Tong TY, et al. Definitions and potential health benefits of the Mediterranean diet: views from experts around the world. BMC Med. 2014;12(1):112. https:\/\/doi.org\/10.1186\/1741-7015-12-112.","journal-title":"BMC Med"},{"key":"597_CR69","doi-asserted-by":"publisher","unstructured":"Cano Contreras AD, Garc\u00eda Carvajal M, Mart\u00ednez P\u00e9rez GP, et al. Efficacy of the Regional Mexican Diet versus the Mediterranean Diet in Patients with MASLD: A 24-Week Non-Inferiority Trial. Revista Espa\u00f1ola de Enfermedades Digestivas. Published online 2024. https:\/\/doi.org\/10.17235\/reed.2024.10392\/2024","DOI":"10.17235\/reed.2024.10392\/2024"},{"issue":"7","key":"597_CR70","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.clnu.2024.05.042","volume":"43","author":"P Mogna-Pel\u00e1ez","year":"2024","unstructured":"Mogna-Pel\u00e1ez P, Riezu-Boj JI, Milagro FI, et al. Inflammatory markers as diagnostic and precision nutrition tools for metabolic dysfunction-associated steatotic liver disease: Results from the Fatty Liver in Obesity trial. Clin Nutr. 2024;43(7):1770\u201381. https:\/\/doi.org\/10.1016\/j.clnu.2024.05.042.","journal-title":"Clin Nutr"},{"issue":"10","key":"597_CR71","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/apt.17941","volume":"59","author":"A Armandi","year":"2024","unstructured":"Armandi A, Bespaljko H, Mang A, et al. Short-term reduction of dietary gluten improves metabolic-dysfunction associated steatotic liver disease: A randomised, controlled proof-of-concept study. Aliment Pharmacol Ther. 2024;59(10):1212\u201322. https:\/\/doi.org\/10.1111\/apt.17941.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"597_CR72","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","volume":"72","author":"A Albillos","year":"2020","unstructured":"Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020;72(3):558\u201377. https:\/\/doi.org\/10.1016\/j.jhep.2019.10.003.","journal-title":"J Hepatol"},{"issue":"5","key":"597_CR73","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1053\/j.gastro.2016.12.006","volume":"152","author":"VF Zevallos","year":"2017","unstructured":"Zevallos VF, Raker V, Tenzer S, et al. Nutritional Wheat Amylase-Trypsin Inhibitors Promote Intestinal Inflammation via Activation of Myeloid Cells. Gastroenterology. 2017;152(5):1100\u20131113.e12. https:\/\/doi.org\/10.1053\/j.gastro.2016.12.006.","journal-title":"Gastroenterology"},{"issue":"1","key":"597_CR74","doi-asserted-by":"publisher","first-page":"17463","DOI":"10.1038\/s41598-019-53323-x","volume":"9","author":"M Ashfaq-Khan","year":"2019","unstructured":"Ashfaq-Khan M, Aslam M, Qureshi MA, et al. Dietary wheat amylase trypsin inhibitors promote features of murine non-alcoholic fatty liver disease. Sci Rep. 2019;9(1):17463. https:\/\/doi.org\/10.1038\/s41598-019-53323-x.","journal-title":"Sci Rep"},{"issue":"13","key":"597_CR75","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.3390\/nu16132008","volume":"16","author":"GD Cazac","year":"2024","unstructured":"Cazac GD, Mihai BM, \u0218tef\u0103nescu G, et al. Celiac Disease, Gluten-Free Diet and Metabolic Dysfunction-Associated Steatotic Liver Disease. Nutrients. 2024;16(13):2008. https:\/\/doi.org\/10.3390\/nu16132008.","journal-title":"Nutrients"},{"issue":"4","key":"597_CR76","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/MEG.0000000000002715","volume":"36","author":"MT Abuelazm","year":"2024","unstructured":"Abuelazm MT, Mohamed I, Naeem A, et al. Intermittent fasting regimens for metabolic dysfunction-associated steatotic liver disease: a systematic review and network meta-analysis of randomized controlled trials. Eur J Gastroenterol Hepatol. 2024;36(4):371\u201381. https:\/\/doi.org\/10.1097\/MEG.0000000000002715.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"13","key":"597_CR77","doi-asserted-by":"publisher","first-page":"3893","DOI":"10.3390\/jcm13133893","volume":"13","author":"M Ahmed","year":"2024","unstructured":"Ahmed M, Ahmed MH. Ramadan Fasting in Individuals with Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Transplant, and Bariatric Surgery: A Narrative Review. J Clin Med. 2024;13(13):3893. https:\/\/doi.org\/10.3390\/jcm13133893.","journal-title":"J Clin Med"},{"issue":"13","key":"597_CR78","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.3390\/nu16132027","volume":"16","author":"G Castelnuovo","year":"2024","unstructured":"Castelnuovo G, Perez-Diaz-del-Campo N, Rosso C, Armandi A, Caviglia GP, Bugianesi E. A Healthful Plant-Based Diet as an Alternative Dietary Approach in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease. Nutrients. 2024;16(13):2027. https:\/\/doi.org\/10.3390\/nu16132027.","journal-title":"Nutrients"},{"key":"597_CR79","doi-asserted-by":"publisher","unstructured":"ANNUNZIATA G, CAP\u00d3 X, MUSCOGIURI G, COLAO A, BARREA L. Intermittent fasting: a new trend or a valid approach for the treatment of obesity? Minerva Endocrinology. 2023;48(4). https:\/\/doi.org\/10.23736\/S2724-6507.23.04100-3","DOI":"10.23736\/S2724-6507.23.04100-3"},{"issue":"3","key":"597_CR80","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7570\/jomes23052","volume":"32","author":"WK Chan","year":"2023","unstructured":"Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. J Obes Metab Syndr. 2023;32(3):197\u2013213. https:\/\/doi.org\/10.7570\/jomes23052.","journal-title":"J Obes Metab Syndr"},{"issue":"6","key":"597_CR81","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1002\/hep.32578","volume":"76","author":"DH Sinn","year":"2022","unstructured":"Sinn DH, Kang D, Kang M, et al. Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort study. Hepatology. 2022;76(6):1746\u201354. https:\/\/doi.org\/10.1002\/hep.32578.","journal-title":"Hepatology"},{"key":"597_CR82","doi-asserted-by":"publisher","unstructured":"Zhu Y, Yang H, Zhang Y, et al. Dietary fiber intake and non-alcoholic fatty liver disease: The mediating role of obesity. Front Public Health. 2023;10. https:\/\/doi.org\/10.3389\/fpubh.2022.1038435","DOI":"10.3389\/fpubh.2022.1038435"},{"issue":"2","key":"597_CR83","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1093\/nutrit\/nuv063","volume":"74","author":"CJ Rebello","year":"2016","unstructured":"Rebello CJ, O\u2019Neil CE, Greenway FL. Dietary fiber and satiety: the effects of oats on satiety. Nutr Rev. 2016;74(2):131\u201347. https:\/\/doi.org\/10.1093\/nutrit\/nuv063.","journal-title":"Nutr Rev"},{"issue":"27","key":"597_CR84","doi-asserted-by":"publisher","first-page":"8752","DOI":"10.1080\/10408398.2022.2061909","volume":"63","author":"IS Waddell","year":"2023","unstructured":"Waddell IS, Orfila C. Dietary fiber in the prevention of obesity and obesity-related chronic diseases: From epidemiological evidence to potential molecular mechanisms. Crit Rev Food Sci Nutr. 2023;63(27):8752\u201367. https:\/\/doi.org\/10.1080\/10408398.2022.2061909.","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"3","key":"597_CR85","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.nut.2004.08.018","volume":"21","author":"JL Slavin","year":"2005","unstructured":"Slavin JL. Dietary fiber and body weight. Nutrition. 2005;21(3):411\u20138. https:\/\/doi.org\/10.1016\/j.nut.2004.08.018.","journal-title":"Nutrition"},{"issue":"5","key":"597_CR86","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1753-4887.2001.tb07001.x","volume":"59","author":"NC Howarth","year":"2009","unstructured":"Howarth NC, Saltzman E, Roberts SB. Dietary Fiber and Weight Regulation. Nutr Rev. 2009;59(5):129\u201339. https:\/\/doi.org\/10.1111\/j.1753-4887.2001.tb07001.x.","journal-title":"Nutr Rev"},{"issue":"5","key":"597_CR87","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.numecd.2020.12.032","volume":"31","author":"M Schoeneck","year":"2021","unstructured":"Schoeneck M, Iggman D. The effects of foods on LDL cholesterol levels: A systematic review of the accumulated evidence from systematic reviews and meta-analyses of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2021;31(5):1325\u201338. https:\/\/doi.org\/10.1016\/j.numecd.2020.12.032.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"597_CR88","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ejim.2024.01.005","volume":"122","author":"A Armandi","year":"2024","unstructured":"Armandi A, Bugianesi E. Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease. Eur J Intern Med. 2024;122:20\u20137. https:\/\/doi.org\/10.1016\/j.ejim.2024.01.005.","journal-title":"Eur J Intern Med"},{"issue":"9","key":"597_CR89","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1001\/jamainternmed.2019.2248","volume":"179","author":"DA Koutoukidis","year":"2019","unstructured":"Koutoukidis DA, Astbury NM, Tudor KE, et al. Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease. JAMA Intern Med. 2019;179(9):1262. https:\/\/doi.org\/10.1001\/jamainternmed.2019.2248.","journal-title":"JAMA Intern Med"},{"key":"597_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154455","volume":"115","author":"DA Koutoukidis","year":"2021","unstructured":"Koutoukidis DA, Koshiaris C, Henry JA, et al. The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis. Metabolism. 2021;115: 154455. https:\/\/doi.org\/10.1016\/j.metabol.2020.154455.","journal-title":"Metabolism"},{"key":"597_CR91","doi-asserted-by":"publisher","unstructured":"Haase CL, Lopes S, Olsen AH, Satylganova A, Schnecke V, McEwan P. Weight loss and risk reduction of obesity-related outcomes in 0.5 million people: evidence from a UK primary care database. Int J Obes (Lond). 2021;45(6):1249\u20131258. https:\/\/doi.org\/10.1038\/s41366-021-00788-4","DOI":"10.1038\/s41366-021-00788-4"},{"issue":"5","key":"597_CR92","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797\u2013835. https:\/\/doi.org\/10.1097\/HEP.0000000000000323.","journal-title":"Hepatology"},{"issue":"3","key":"597_CR93","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/00325481.2024.2325332","volume":"136","author":"AM Allen","year":"2024","unstructured":"Allen AM, Charlton M, Cusi K, et al. Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting. Postgrad Med. 2024;136(3):229\u201345. https:\/\/doi.org\/10.1080\/00325481.2024.2325332.","journal-title":"Postgrad Med"},{"issue":"1","key":"597_CR94","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12944-024-02220-y","volume":"23","author":"Y Jin","year":"2024","unstructured":"Jin Y, Wang X, Chen K, et al. Silymarin decreases liver stiffness associated with gut microbiota in patients with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, placebo-controlled trial. Lipids Health Dis. 2024;23(1):239. https:\/\/doi.org\/10.1186\/s12944-024-02220-y.","journal-title":"Lipids Health Dis"},{"issue":"1","key":"597_CR95","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12937-024-00911-x","volume":"23","author":"S Ebrahimpour-Koujan","year":"2024","unstructured":"Ebrahimpour-Koujan S, Sohrabpour AA, Giovannucci E, Vatannejad A, Esmaillzadeh A. Effects of vitamin D supplementation on liver fibrogenic factors, vitamin D receptor and liver fibrogenic microRNAs in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: an exploratory randomized clinical trial. Nutr J. 2024;23(1):24. https:\/\/doi.org\/10.1186\/s12937-024-00911-x.","journal-title":"Nutr J"},{"issue":"2","key":"597_CR96","doi-asserted-by":"publisher","first-page":"184","DOI":"10.2478\/rjim-2024-0004","volume":"62","author":"M Mitrovi\u0107","year":"2024","unstructured":"Mitrovi\u0107 M, Dobrosavljevi\u0107 A, Odanovi\u0107 O, et al. The effects of synbiotics on the liver steatosis, inflammation, and gut microbiome of metabolic dysfunction-associated liver disease patients-randomized trial. Rom J Intern Med. 2024;62(2):184\u201393. https:\/\/doi.org\/10.2478\/rjim-2024-0004.","journal-title":"Rom J Intern Med"},{"key":"597_CR97","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59(6):1121\u20131140. https:\/\/doi.org\/10.1007\/s00125-016-3902-y","DOI":"10.1007\/s00125-016-3902-y"},{"key":"597_CR98","doi-asserted-by":"publisher","unstructured":"Sabinari I, Horakova O, Cajka T, Kleinova V, Wieckowski M, Rossmeisl M. Influence of Lipid Class Used for Omega-3 Fatty Acid Supplementation on Liver Fat Accumulation in MASLD. Physiol Res. 2024;(Suppl 1):S295-S320. https:\/\/doi.org\/10.33549\/physiolres.935396","DOI":"10.33549\/physiolres.935396"},{"issue":"10","key":"597_CR99","doi-asserted-by":"publisher","first-page":"5238","DOI":"10.3390\/ijms25105238","volume":"25","author":"A Sokal-Dembowska","year":"2024","unstructured":"Sokal-Dembowska A, Jarmakiewicz-Czaja S, Ferenc K, Filip R. Can Nutraceuticals Support the Treatment of MASLD\/MASH, and thus Affect the Process of Liver Fibrosis? Int J Mol Sci. 2024;25(10):5238. https:\/\/doi.org\/10.3390\/ijms25105238.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"597_CR100","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5507\/bp.2005.002","volume":"149","author":"V K\u0159en","year":"2005","unstructured":"K\u0159en V, Walterov\u00e1 D. Silybin and silymarin - new effects and applications. Biomedical Papers. 2005;149(1):29\u201341. https:\/\/doi.org\/10.5507\/bp.2005.002.","journal-title":"Biomedical Papers"},{"issue":"1","key":"597_CR101","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3138\/canlivj-2023-0021","volume":"7","author":"A Malik","year":"2024","unstructured":"Malik A, Malik M, Qureshi S. Effects of silymarin use on liver enzymes and metabolic factors in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. Canadian Liver Journal. 2024;7(1):40\u201353. https:\/\/doi.org\/10.3138\/canlivj-2023-0021.","journal-title":"Canadian Liver Journal"},{"issue":"24","key":"597_CR102","doi-asserted-by":"publisher","first-page":"5053","DOI":"10.3390\/nu15245053","volume":"15","author":"M Guariglia","year":"2023","unstructured":"Guariglia M, Saba F, Rosso C, Bugianesi E. Molecular Mechanisms of Curcumin in the Pathogenesis of Metabolic Dysfunction Associated Steatotic Liver Disease. Nutrients. 2023;15(24):5053. https:\/\/doi.org\/10.3390\/nu15245053.","journal-title":"Nutrients"},{"issue":"5","key":"597_CR103","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3390\/antiox10050708","volume":"10","author":"A Deledda","year":"2021","unstructured":"Deledda A, Annunziata G, Tenore GC, Palmas V, Manzin A, Velluzzi F. Diet-Derived Antioxidants and Their Role in Inflammation, Obesity and Gut Microbiota Modulation. Antioxidants. 2021;10(5):708. https:\/\/doi.org\/10.3390\/antiox10050708.","journal-title":"Antioxidants"},{"issue":"6","key":"597_CR104","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3390\/metabo14060346","volume":"14","author":"A Zi\u00f3\u0142kiewicz","year":"2024","unstructured":"Zi\u00f3\u0142kiewicz A, Nizi\u0144ski P, Soja J, et al. Potential of Chlorogenic Acid in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Animal Studies and Clinical Trials\u2014A Narrative Review. Metabolites. 2024;14(6):346. https:\/\/doi.org\/10.3390\/metabo14060346.","journal-title":"Metabolites"},{"issue":"7","key":"597_CR105","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.3390\/ijms25073746","volume":"25","author":"K Kasprzak-Drozd","year":"2024","unstructured":"Kasprzak-Drozd K, Nizi\u0144ski P, Kasprzak P, et al. Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)? Int J Mol Sci. 2024;25(7):3746. https:\/\/doi.org\/10.3390\/ijms25073746.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"597_CR106","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1111\/dom.15755","volume":"26","author":"SA Willis","year":"2024","unstructured":"Willis SA, Malaikah S, Bawden SJ, et al. Greater hepatic lipid saturation is associated with impaired glycaemic regulation in men with metabolic dysfunction-associated steatotic liver disease but is not altered by 6 weeks of exercise training. Diabetes Obes Metab. 2024;26(9):4030\u201342. https:\/\/doi.org\/10.1111\/dom.15755.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"597_CR107","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1002\/oby.23887","volume":"31","author":"E Tas","year":"2023","unstructured":"Tas E, Landes RD, Diaz EC, et al. Effects of short-term supervised exercise training on liver fat in adolescents with obesity: a randomized controlled trial. Obesity (Silver Spring). 2023;31(11):2740\u20139. https:\/\/doi.org\/10.1002\/oby.23887.","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"597_CR108","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/1753-0407.13086","volume":"13","author":"CJ Baker","year":"2021","unstructured":"Baker CJ, Martinez-Huenchullan SF, D\u2019Souza M, et al. Effect of exercise on hepatic steatosis: Are benefits seen without dietary intervention? A systematic review and <scp>meta-analysis<\/scp>. J Diabetes. 2021;13(1):63\u201377. https:\/\/doi.org\/10.1111\/1753-0407.13086.","journal-title":"J Diabetes"},{"issue":"8","key":"597_CR109","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/apt.15989","volume":"52","author":"P O\u2019Gorman","year":"2020","unstructured":"O\u2019Gorman P, Naimimohasses S, Monaghan A, et al. Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention. Aliment Pharmacol Ther. 2020;52(8):1387\u201398. https:\/\/doi.org\/10.1111\/apt.15989.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"597_CR110","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328\u201357. https:\/\/doi.org\/10.1002\/hep.29367.","journal-title":"Hepatology"},{"issue":"3","key":"597_CR111","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","volume":"160","author":"ZM Younossi","year":"2021","unstructured":"Younossi ZM, Corey KE, Lim JK. AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology. 2021;160(3):912\u20138. https:\/\/doi.org\/10.1053\/j.gastro.2020.11.051.","journal-title":"Gastroenterology"},{"issue":"2","key":"597_CR112","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263931","volume":"17","author":"T Fern\u00e1ndez","year":"2022","unstructured":"Fern\u00e1ndez T, Vi\u00f1uela M, Vidal C, Barrera F. Lifestyle changes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. PLoS ONE. 2022;17(2): e0263931. https:\/\/doi.org\/10.1371\/journal.pone.0263931.","journal-title":"PLoS ONE"},{"key":"597_CR113","doi-asserted-by":"publisher","unstructured":"Abenavoli L, Gambardella ML, Scarlata GGM, Lenci I, Baiocchi L, Luzza F. The Many Faces of Metabolic Dysfunction-Associated Fatty Liver Disease Treatment: From the Mediterranean Diet to Fecal Microbiota Transplantation. Medicina (Kaunas). 2024;60(4). https:\/\/doi.org\/10.3390\/medicina60040563","DOI":"10.3390\/medicina60040563"},{"key":"597_CR114","doi-asserted-by":"publisher","unstructured":"Verde L, Dalamaga M, Cap\u00f3 X, et al. The Antioxidant Potential of the Mediterranean Diet as a Predictor of Weight Loss after a Very Low-Calorie Ketogenic Diet (VLCKD) in Women with Overweight and Obesity. Antioxidants (Basel). 2022;12(1). https:\/\/doi.org\/10.3390\/antiox12010018","DOI":"10.3390\/antiox12010018"},{"key":"597_CR115","doi-asserted-by":"publisher","unstructured":"Mart\u00edn-Fern\u00e1ndez M, Arroyo V, Carnicero C, et al. Role of Oxidative Stress and Lipid Peroxidation in the Pathophysiology of NAFLD. Antioxidants (Basel). 2022;11(11). https:\/\/doi.org\/10.3390\/antiox11112217","DOI":"10.3390\/antiox11112217"},{"key":"597_CR116","doi-asserted-by":"publisher","unstructured":"Barrea L, Verde L, Savastano S, Colao A, Muscogiuri G. Adherence to Mediterranean Diet: Any Association with NAFLD? Antioxidants (Basel). 2023;12(7). https:\/\/doi.org\/10.3390\/antiox12071318","DOI":"10.3390\/antiox12071318"},{"issue":"2","key":"597_CR117","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1017\/S000711451800137X","volume":"120","author":"CN Katsagoni","year":"2018","unstructured":"Katsagoni CN, Papatheodoridis GV, Ioannidou P, et al. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial. Br J Nutr. 2018;120(2):164\u201375. https:\/\/doi.org\/10.1017\/S000711451800137X.","journal-title":"Br J Nutr"},{"issue":"5","key":"597_CR118","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/hep.30076","volume":"68","author":"C Properzi","year":"2018","unstructured":"Properzi C, O\u2019Sullivan TA, Sherriff JL, et al. Ad Libitum Mediterranean and Low-Fat Diets Both Significantly Reduce Hepatic Steatosis: A Randomized Controlled Trial. Hepatology. 2018;68(5):1741\u201354. https:\/\/doi.org\/10.1002\/hep.30076.","journal-title":"Hepatology"},{"issue":"1","key":"597_CR119","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/nu13010015","volume":"13","author":"D Ristic-Medic","year":"2020","unstructured":"Ristic-Medic D, Kovacic M, Takic M, et al. Calorie-Restricted Mediterranean and Low-Fat Diets Affect Fatty Acid Status in Individuals with Nonalcoholic Fatty Liver Disease. Nutrients. 2020;13(1):15. https:\/\/doi.org\/10.3390\/nu13010015.","journal-title":"Nutrients"},{"issue":"26","key":"597_CR120","doi-asserted-by":"publisher","first-page":"8320","DOI":"10.1080\/10408398.2022.2054935","volume":"63","author":"L Barrea","year":"2023","unstructured":"Barrea L, Caprio M, Watanabe M, et al. Could very low-calorie ketogenic diets turn off low grade inflammation in obesity? Emerging evidence. Crit Rev Food Sci Nutr. 2023;63(26):8320\u201336. https:\/\/doi.org\/10.1080\/10408398.2022.2054935.","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"1","key":"597_CR121","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12967-023-03880-7","volume":"21","author":"C Vetrani","year":"2023","unstructured":"Vetrani C, Verde L, Savastano S, Colao A, Muscogiuri G, Barrea L. Supplementation with medium-chain fatty acids increases body weight loss during very low-calorie ketogenic diet: a retrospective analysis in a real-life setting. J Transl Med. 2023;21(1):29. https:\/\/doi.org\/10.1186\/s12967-023-03880-7.","journal-title":"J Transl Med"},{"issue":"5","key":"597_CR122","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/jcm8050621","volume":"8","author":"S Ministrini","year":"2019","unstructured":"Ministrini S, Calzini L, Nulli Migliola E, et al. Lysosomal Acid Lipase as a Molecular Target of the Very Low Carbohydrate Ketogenic Diet in Morbidly Obese Patients: The Potential Effects on Liver Steatosis and Cardiovascular Risk Factors. J Clin Med. 2019;8(5):621. https:\/\/doi.org\/10.3390\/jcm8050621.","journal-title":"J Clin Med"},{"issue":"8","key":"597_CR123","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1136\/gutjnl-2023-329998","volume":"72","author":"T Marjot","year":"2023","unstructured":"Marjot T, Tomlinson JW, Hodson L, Ray DW. Timing of energy intake and the therapeutic potential of intermittent fasting and time-restricted eating in NAFLD. Gut. 2023;72(8):1607\u201319. https:\/\/doi.org\/10.1136\/gutjnl-2023-329998.","journal-title":"Gut"},{"issue":"9","key":"597_CR124","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/s41366-022-01159-3","volume":"46","author":"C Vetrani","year":"2022","unstructured":"Vetrani C, Barrea L, Verde L, et al. Evening chronotype is associated with severe NAFLD in obesity. Int J Obes. 2022;46(9):1638\u201343. https:\/\/doi.org\/10.1038\/s41366-022-01159-3.","journal-title":"Int J Obes"},{"key":"597_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2020.08.071","volume":"20","author":"U Hayat","year":"2021","unstructured":"Hayat U, Siddiqui AA, Okut H, Afroz S, Tasleem S, Haris A. The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: A meta-analysis of 11 epidemiological studies. Ann Hepatol. 2021;20: 100254. https:\/\/doi.org\/10.1016\/j.aohep.2020.08.071.","journal-title":"Ann Hepatol"},{"issue":"6","key":"597_CR126","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1016\/j.clnu.2018.11.030","volume":"38","author":"YP Chen","year":"2019","unstructured":"Chen YP, Lu FB, Hu YB, Xu LM, Zheng MH, Hu ED. A systematic review and a dose\u2013response meta-analysis of coffee dose and nonalcoholic fatty liver disease. Clin Nutr. 2019;38(6):2552\u20137. https:\/\/doi.org\/10.1016\/j.clnu.2018.11.030.","journal-title":"Clin Nutr"},{"issue":"9","key":"597_CR127","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1016\/j.cgh.2021.09.042","volume":"20","author":"S Niezen","year":"2022","unstructured":"Niezen S, Mehta M, Jiang ZG, Tapper EB. Coffee Consumption Is Associated With Lower Liver Stiffness: A Nationally Representative Study. Clin Gastroenterol Hepatol. 2022;20(9):2032\u20132040.e6. https:\/\/doi.org\/10.1016\/j.cgh.2021.09.042.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Current Obesity Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-024-00597-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13679-024-00597-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-024-00597-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:22:39Z","timestamp":1736554959000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13679-024-00597-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,11]]},"references-count":127,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["597"],"URL":"https:\/\/doi.org\/10.1007\/s13679-024-00597-6","relation":{},"ISSN":["2162-4968"],"issn-type":[{"value":"2162-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,11]]},"assertion":[{"value":"3 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"7"}}